Skip to content
    Reviews

    Postoperative ctDNA for Risk Stratification in Resectable Esophageal Squamous Cell Carcinoma

    Sagawa et alJournal of gastrointestinal cancer

    Postoperative ctDNA for Risk Stratification in Resectable Esophageal Squamous Cell Carcinoma
    A structured narrative review evaluated perioperative and postoperative circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection in resectable esophageal squamous cell carcinoma (ESCC), synthesizing data from PubMed/MEDLINE through August 17, 2026, citation tracking, and clinical trial registries. Across cohorts utilizing digital PCR, fixed next-generation sequencing panels, and personalized tumor-informed assays, postoperative ctDNA positivity consistently identifies individuals at increased risk of disease recurrence, although estimates remain imprecise due to small cohort sizes. In addition, longitudinal serial testing can detect molecular relapse months prior to radiographic recurrence.
    Integrated models incorporating histopathology and MRD status demonstrate additional risk stratification within both pathological complete response and non-complete response subgroups. Observational findings suggest, but do not establish, that MRD-positive patients may derive greater benefit from adjuvant immunotherapy. Conversely, postoperative MRD negativity alone does not justify omitting indicated adjuvant treatment. The authors conclude that although ctDNA provides complementary molecular risk information beyond conventional pathology, prospective MRD-guided trials are required before postoperative treatment or surveillance strategies can be routinely modified based on ctDNA results alone.

    Key Takeaways

    • Postoperative ctDNA positivity across digital PCR, fixed next-generation sequencing panels, and personalized tumor-informed assays consistently identifies patients with resectable ESCC at increased risk of recurrence, with serial testing detecting molecular relapse months before radiographic recurrence.
    • Integrated pathology-MRD models demonstrate additional recurrence risk stratification within both pathological complete response and non-complete response cohorts, but ctDNA negativity alone does not justify omitting indicated adjuvant therapy.
    • Observational findings suggest, but do not establish, that MRD-positive patients may derive greater benefit from adjuvant immunotherapy, indicating that prospective MRD-guided trials are required before treatment or surveillance strategies can be routinely altered based on ctDNA status alone.
    Read the original sourceJournal of gastrointestinal cancer